KolateAI

KolateAI provides patient-level Clinical Events Prediction to accelerate pharma trials and real-world studies. With our AI foundation models trained on clinical studies delivered through our Co-pilot, we predict major clinical events (drug response, adverse events, study end-points). This enables pharmas to target the best-performing patient segments and pro-actively manage study trajectory.

Circadian OS

Harmonigenic Corporation

Harmonigenic Corporation is a biotech company focused on developing a novel optical assay diagnostic called OPTIM (Optical Prediction of Time Interval to Metastasis). OPTIM aims to improve personalized medicine by providing treatment guidance for breast and colon cancer patients at the time of diagnosis. The platform assay uses SHG two-photon light scatter of collagen in the extracellular matrix of the primary tumor to detect the metastatic phenotype of cancer tissue. By identifying cancers that have already spread at Stage 1 and are at high risk of recurrence to Stage 4, OPTIM can help guide treatment decisions and prevent overtreatment. A patent with inventor and company founder Robert L. Hill, M.D., has been granted in Europe and pending in the USA covers using OPTIM to predict the response to neoadjuvant chemotherapy. The company is seeking $10 million in seed equity financing and $1 million per year in SBIR grants. They plan to operate a CLIA laboratory in Rochester, NY and price the OPTIM assay at about $3,000. Harmonigenic Corporation started working in 2015 with Edward Brown’s laboratory at the University of Rochester which has been funded by Federal grants from the DoD Breast Cancer Research Program, NIH, and NCI of over $7 Million so far. Their financial projections show significant revenue comparable to what has been seen with OncotypeDX. Genomic Health was acquired in 2019 for $2.8 Billion by Exact Sciences. Overall, Harmonigenic Corporation aims to become part of the standard of care diagnostic data presented to tumor boards and provide personalized cancer treatment decisions.

DirectSeq Biosciences Inc.

DirectSeq Biosciences Inc. (DSI) is a biotech startup supported by NIH STTR grant funding and New York State Matchup funding. It has patented mass spectrometry-based sequencing technologies that are complementary to current high throughput sequencing technologies. DSI is unique positioned and specialized in direct sequencing of RNAs de novo and systematic mapping of RNA modifications quantitatively, and thus enabling to decipher the true informational content of RNA, including both four (4) canonical nucleotides (A, C, G, and U) or various modified nucleotides (>170 different modification types), that is a big challenge in RNA sequencing and no other sequencing method can achieve. DSI is now seeking motivated personnel and investors to help grow the company into a major player in the genomics industry.

Fzata, Inc.

Fzata’s vision is to be the world leader in oral biologics. We have captured the “holy grail” of oral biologics with our first-in-class live Bioengineered Probiotic Yeast Medicines (BioPYMTM) Platform. Our mission is to transform patient safety, efficacy & access to biologics with BioPYM. NIH has vetted and validated our platform; designating Fzata as an NIH Seed Company with over $24MM in grants plus more pending. Fzata was honored to be a Startup Stadium Finalist at BIO2024.

The oral BioPYM platform acts as a micro-factory in the gut making therapeutic restricted to the disease site for GI diseases and disorders. BioPYM can make any therapeutic protein including monoclonal antibodies, enzymes, cytokines, and hormones. The BioPYM international patent portfolio is owned by Fzata. Indications include: inflammatory bowel disease (IBD), C. diff infection, diabetes, and abdominal pain.

BioPYM competitive advantages compared to conventional parenteral injectables include 1) Improved Patient QoL: better outcomes, no needles, no clinic infusions 2) Clinical benefits: no trough/peaks in drug level, no side-effects from systemic distribution, OK to use with antibiotics, no anti-drug antibody response, no concomitant immunosuppressant, microbiota support, 3) Manufacturing benefits: low cost of goods, no cold-chain, cross-over manufacturing efficiencies among drug candidates, scalable, no down-stream biologic purification.

· FZ002 for C. diff infection, is on schedule for an NIH supported first-in-human trial in 2025. Successful readout will prove the safety of BioPYM and derisk CMC and regulatory path for other BioPYM candidates.

· FZ006 for IBD expresses an anti-TNFa (like Humira® or Remicade®). It has completed animal efficacy. FZ006 will be the first oral anti-TNFa. TAM for FZ006 >$10B. FZ006 is also being developed for visceral pain and is recently supported by a $7MM NIH grant.

$22M series A raise in 1H2025 to support development of FZ006 through completion of Phase 1, pipeline activities, facilities and G&A. We are also seeking pharma partners for our assets.

For inquiries please contact Elizabeth_Smith@fzata.com

Micoy Therapeutics

Micoy Therapeutics aims to block harmful autoantibodies that lead to life-threatening infections and may promote malignancies. Approximately 20% of life-threatening COVID-19 cases and fatalities can be attributed to autoantibodies that disable the immune system, and similar effects have been seen with other common viruses such as influenza, cytomegalovirus, herpes, zika, dengue, etc. Unfortunately, these autoantibodies are prevalent in 5-10% of individuals over 65 years of age, and people with autoantibodies that block type I interferons are 100X more likely to develop life threatening disease upon infection. Our team has developed several decoy therapeutic candidates that show promise in blocking these harmful autoantibodies and are raising funds to propel our lead asset to IND.

Onselex Pharmaceuticals

Serinus Biosciences, Inc.

Serinus Bio is an AI drug discovery company uniquely focused on overcoming cancer treatment resistance. We develop therapeutics that can treat multiple patient populations with a single drug. Our many-to-one synthetic lethality platform reveals cellular vulnerabilities that are shared across multiple resistant populations. By combining seemingly singular populations we can treat tens of thousands of patients that remain overlooked by others. Our lead program targets a cell-cycle resistance mechanism that is present in more than 10% of solid tumors. Our work was published in top journals, including Science, Nature Biotech, and Cell.

Pannex Therapeutics

Pannex Therapeutics is an early-stage pharma startup developing a new class of drugs, the Pannexin 1 channel (Panx1) blockers, as a targeted therapy to improve current treatments against Triple-Negative Breast Cancer (TNBC), the most aggressive of its type

OmniCyte